Welcome to our dedicated news page for DexCom (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on DexCom.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DexCom's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DexCom's position in the market.
Rhea-AI Summary
Dexcom, Inc. (Nasdaq: DXCM) has announced the launch of the Dexcom G7 Continuous Glucose Monitoring (CGM) System, which now connects with the t:slim X2 insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa. The system combines the power and accuracy of Dexcom G7 with the discretion of the Tandem t:slim X2. Dexcom is recognized as the most clinically studied CGM brand with AID capabilities, with more than 1 million patient years of cumulative use. New results from the COMISAIR seven-year follow up show significant and continued reduction of HbA1c as well as a lower risk of the development or progression of diabetic retinopathy associated with the use of real-time CGM by people with Type 1 diabetes. Dexcom G7 is the fastest CGM connected to the t:slim X2 insulin pump, with a 30-minute sensor warmup time, and offers industry-leading remote monitoring capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
DexCom, Inc. (DXCM) expects significant revenue growth in 2023, with unaudited revenue for the fourth quarter projected to be at least $1.030 billion, a 26% increase over the same period in 2022. The company anticipates total revenue for fiscal 2023 to be approximately $3.62 billion, a 24% increase over 2022. DexCom also announced the submission of Stelo, a new glucose sensor for people with type 2 diabetes who do not use insulin, to the U.S. FDA for review, with an expected launch in the U.S. in summer 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
-
Rhea-AI Summary
DexCom, Inc. (NASDAQ:DXCM) will present an update at the 42nd annual J.P. Morgan Healthcare Conference on January 8, 2024. The live presentation by Kevin Sayer, Chairman, President, and CEO, will be webcast and archived on the Dexcom Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
Rhea-AI Summary
Synchron (SYN) announces the appointment of Andy Rasdal to its Board of Directors. Rasdal brings over 30 years of experience in developing and commercializing novel medical devices. He has led companies through FDA approval, IPO, and commercialization of innovative products, making him a valuable addition to Synchron's board. His career exposure to over 15 PMAs, particularly leading DexCom through FDA approval and eventual IPO, will be invaluable to Synchron. Rasdal's expertise will be crucial as Synchron moves towards pivotal study launch and eventual commercialization of its implantable brain-computer interface technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
-
Rhea-AI Summary
DexCom, Inc. (Nasdaq: DXCM) announced the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM, the world’s most accurate CGM system. The clinically meaningful health outcomes that result from using the t:slim X2 insulin pump with Control-IQ technology are proven only when the system is connected to Dexcom CGM technology. The COMISAIR seven-year follow up showed significant and continued reduction of HbA1c as well as a lower risk of the development or progression of diabetic retinopathy associated with the use of real-time CGM by people with Type 1 diabetes. Additionally, the COMISAIR seven-year follow up demonstrated further substantial reduction in HbA1c when Dexcom CGM is connected to the Tandem t:slim X2 insulin pump with Control-IQ technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
-
Rhea-AI Summary
Dexcom, Inc. (Nasdaq: DXCM) announces the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2 insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM. Dexcom G7 is the smallest, most accurate CGM system currently connected to the t:slim X2 insulin pump. The launch of Dexcom G7 and the Tandem t:slim X2 insulin pump further strengthens Dexcom’s position as the world’s most connected CGM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
Rhea-AI Summary
DexCom, Inc. (DXCM) to Present at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
DexCom, Inc. (NASDAQ: DXCM) Unveils #SeeDiabetes Campaign and Portrait Gallery to Raise Awareness for Expanding Access to Diabetes Technology. The campaign features a first-of-its-kind global portrait gallery of people living with diabetes, including celebrities Nick Jonas, Patti LaBelle, and Jeremy Irvine. Dexcom's efforts have expanded CGM coverage by 6 million people globally, reinforcing their commitment to broadening access to critical diabetes technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
-
Rhea-AI Summary
DexCom, Inc. (NASDAQ: DXCM) announces new market research and NICE recommendations on the benefits of Hybrid Closed Loop Systems (HCL) for people with diabetes. The research indicates that 79% of people struggle to keep their glucose levels in range, and almost half don't understand the benefits of HCL. The NICE TA for HCL systems will impact over 150,000 people living with Type 1 diabetes in England.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
Rhea-AI Summary
DexCom reports Q3 2023 financial results with revenue growth of 27% to $975.0 million. The company secures reimbursement for Dexcom ONE in France and receives regulatory clearance for Dexcom G7 in Canada. DexCom raises its full-year revenue and margin guidance and announces a $500 million share repurchase program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.11%
Tags
DexCom, Inc.
Nasdaq:DXCM
DXCM Rankings
DXCM Stock Data
50.66B
379.71M
0.41%
103.06%
3.78%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
SAN DIEGO
About DXCM
founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.